| . | Derivation cohort . | Validation cohort . | ||||
|---|---|---|---|---|---|---|
| . | All visits . | MI . | No MI . | All visits . | MI . | No MI . |
| Number of visits | 60 071 (100) | 2999 (5.0) | 57 072 (95) | 10 994 (100) | 582 (5.3) | 10 412 (95) |
| Age (years) | 68 (56–79) | 76 (67–86) | 68 (56–79) | 68 (54.0–79.0) | 75 (67–85) | 68 (53–78) |
| Women | 28 476 (47) | 1164 (2) | 27 312 (46) | 5436 (49) | 242 (42) | 5194 (50) |
| Comorbidities | ||||||
| Prior stroke | 6012 (10) | 470 (16) | 5542 (10) | 1514 (14) | 111 (19) | 1403 (14) |
| Prior MIa | 17 223 (29) | 1692 (56) | 15 531 (27) | 2449 (22) | 267 (46) | 2182 (21) |
| COPD | 7463 (12) | 403 (13) | 7060 (12) | 938 (8.5) | 49 (8.4) | 889 (8.5) |
| Heart failure | 8576 (14) | 583 (19) | 7993 (14) | 1563 (14) | 125 (22) | 1438 (14) |
| Diabetes | 10 263 (17) | 939 (31) | 9324 (16) | 2430 (22) | 210 (36) | 2220 (21) |
| Chronic kidney disease (eGFR < 60 mL/min/1.73 m2) | 4069 (6.8) | 464 (16) | 3605 (6.3) | 770 (7.0) | 84 (14) | 686 (6.6) |
| Current medications | ||||||
| Aspirin | 23 571 (39) | 1837 (61) | 21 734 (38) | 2889 (26) | 258 (44) | 2631 (25) |
| P2Y12 inhibitors | 8269 (14) | 746 (25) | 7523 (13) | 777 (7.1) | 84 (14) | 693 (6.7) |
| Beta-blockers | 33 037 (55) | 2079 (69) | 30 958 (54) | 2399 (22) | 171 (29) | 2228 (21) |
| ACE/ARB | 28 918 (48) | 1830 (61) | 27 088 (48) | 4012 (37) | 291 (50) | 3721 (36) |
| Statins | 24 664 (41) | 1662 (55) | 23 002 (40) | 3927 (36) | 288 (50) | 3639 (35) |
| NOACb | 2774 (4.6) | 112 (3.7) | 2662 (4.7) | 1072 (9.8) | 50 (8.6) | 1022 (9.8) |
| Warfarin | 8133 (14) | 363 (12) | 7770 (14) | 335 (3.0) | 24 (4.1) | 311 (3.0) |
| OACc | 10 677 (18) | 461 (15) | 10 216 (18) | 1407 (13) | 74 (13) | 1333 (13) |
| Laboratory data | ||||||
| 0 h hs-cTnT level (ng/L) | 10 (5–20) | 44 (21–108) | 9 (5–19) | 9 (5–20) | 50 (23–124) | 9 (4–18) |
| Historical hs-cTnT level (ng/L) | 10 (5–23) | 25 (12–69) | 10 (5–21) | 9 (4.–21) | 20 (10–64) | 9 (4–20) |
| Delta hs-cTnT changed (ng/L) | 2 (1–7) | 33 (9–145) | 2 (1–6) | 2 (1–8) | 42 (11–162) | 2 (0–7) |
| Time from historical hs-cTnT to 0 h hs-cTnT concentration (days) | 147 (40–384) | 152 (41–407) | 146 (40–383) | 465 (165–894) | 503 (147–942) | 463 (166–892) |
| . | Derivation cohort . | Validation cohort . | ||||
|---|---|---|---|---|---|---|
| . | All visits . | MI . | No MI . | All visits . | MI . | No MI . |
| Number of visits | 60 071 (100) | 2999 (5.0) | 57 072 (95) | 10 994 (100) | 582 (5.3) | 10 412 (95) |
| Age (years) | 68 (56–79) | 76 (67–86) | 68 (56–79) | 68 (54.0–79.0) | 75 (67–85) | 68 (53–78) |
| Women | 28 476 (47) | 1164 (2) | 27 312 (46) | 5436 (49) | 242 (42) | 5194 (50) |
| Comorbidities | ||||||
| Prior stroke | 6012 (10) | 470 (16) | 5542 (10) | 1514 (14) | 111 (19) | 1403 (14) |
| Prior MIa | 17 223 (29) | 1692 (56) | 15 531 (27) | 2449 (22) | 267 (46) | 2182 (21) |
| COPD | 7463 (12) | 403 (13) | 7060 (12) | 938 (8.5) | 49 (8.4) | 889 (8.5) |
| Heart failure | 8576 (14) | 583 (19) | 7993 (14) | 1563 (14) | 125 (22) | 1438 (14) |
| Diabetes | 10 263 (17) | 939 (31) | 9324 (16) | 2430 (22) | 210 (36) | 2220 (21) |
| Chronic kidney disease (eGFR < 60 mL/min/1.73 m2) | 4069 (6.8) | 464 (16) | 3605 (6.3) | 770 (7.0) | 84 (14) | 686 (6.6) |
| Current medications | ||||||
| Aspirin | 23 571 (39) | 1837 (61) | 21 734 (38) | 2889 (26) | 258 (44) | 2631 (25) |
| P2Y12 inhibitors | 8269 (14) | 746 (25) | 7523 (13) | 777 (7.1) | 84 (14) | 693 (6.7) |
| Beta-blockers | 33 037 (55) | 2079 (69) | 30 958 (54) | 2399 (22) | 171 (29) | 2228 (21) |
| ACE/ARB | 28 918 (48) | 1830 (61) | 27 088 (48) | 4012 (37) | 291 (50) | 3721 (36) |
| Statins | 24 664 (41) | 1662 (55) | 23 002 (40) | 3927 (36) | 288 (50) | 3639 (35) |
| NOACb | 2774 (4.6) | 112 (3.7) | 2662 (4.7) | 1072 (9.8) | 50 (8.6) | 1022 (9.8) |
| Warfarin | 8133 (14) | 363 (12) | 7770 (14) | 335 (3.0) | 24 (4.1) | 311 (3.0) |
| OACc | 10 677 (18) | 461 (15) | 10 216 (18) | 1407 (13) | 74 (13) | 1333 (13) |
| Laboratory data | ||||||
| 0 h hs-cTnT level (ng/L) | 10 (5–20) | 44 (21–108) | 9 (5–19) | 9 (5–20) | 50 (23–124) | 9 (4–18) |
| Historical hs-cTnT level (ng/L) | 10 (5–23) | 25 (12–69) | 10 (5–21) | 9 (4.–21) | 20 (10–64) | 9 (4–20) |
| Delta hs-cTnT changed (ng/L) | 2 (1–7) | 33 (9–145) | 2 (1–6) | 2 (1–8) | 42 (11–162) | 2 (0–7) |
| Time from historical hs-cTnT to 0 h hs-cTnT concentration (days) | 147 (40–384) | 152 (41–407) | 146 (40–383) | 465 (165–894) | 503 (147–942) | 463 (166–892) |
Data are presented as n (%), mean ± SD, or median with IQR.
Includes only MI as a primary diagnosis.
Includes treatment with Apixaban, Rivaroxaban, Dabigatran, or Epixaban.
Includes treatment with NOAC or warfarin.
The absolute change of hs-cTnT between the historical hs-cTnT and the 0 h cTnT concentration.
ACE/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; hs-cTnT, high-sensitivity cardiac troponin T; MI, myocardial infarction; NOAC, new oral anticoagulants; OAC, oral anticoagulants.
| . | Derivation cohort . | Validation cohort . | ||||
|---|---|---|---|---|---|---|
| . | All visits . | MI . | No MI . | All visits . | MI . | No MI . |
| Number of visits | 60 071 (100) | 2999 (5.0) | 57 072 (95) | 10 994 (100) | 582 (5.3) | 10 412 (95) |
| Age (years) | 68 (56–79) | 76 (67–86) | 68 (56–79) | 68 (54.0–79.0) | 75 (67–85) | 68 (53–78) |
| Women | 28 476 (47) | 1164 (2) | 27 312 (46) | 5436 (49) | 242 (42) | 5194 (50) |
| Comorbidities | ||||||
| Prior stroke | 6012 (10) | 470 (16) | 5542 (10) | 1514 (14) | 111 (19) | 1403 (14) |
| Prior MIa | 17 223 (29) | 1692 (56) | 15 531 (27) | 2449 (22) | 267 (46) | 2182 (21) |
| COPD | 7463 (12) | 403 (13) | 7060 (12) | 938 (8.5) | 49 (8.4) | 889 (8.5) |
| Heart failure | 8576 (14) | 583 (19) | 7993 (14) | 1563 (14) | 125 (22) | 1438 (14) |
| Diabetes | 10 263 (17) | 939 (31) | 9324 (16) | 2430 (22) | 210 (36) | 2220 (21) |
| Chronic kidney disease (eGFR < 60 mL/min/1.73 m2) | 4069 (6.8) | 464 (16) | 3605 (6.3) | 770 (7.0) | 84 (14) | 686 (6.6) |
| Current medications | ||||||
| Aspirin | 23 571 (39) | 1837 (61) | 21 734 (38) | 2889 (26) | 258 (44) | 2631 (25) |
| P2Y12 inhibitors | 8269 (14) | 746 (25) | 7523 (13) | 777 (7.1) | 84 (14) | 693 (6.7) |
| Beta-blockers | 33 037 (55) | 2079 (69) | 30 958 (54) | 2399 (22) | 171 (29) | 2228 (21) |
| ACE/ARB | 28 918 (48) | 1830 (61) | 27 088 (48) | 4012 (37) | 291 (50) | 3721 (36) |
| Statins | 24 664 (41) | 1662 (55) | 23 002 (40) | 3927 (36) | 288 (50) | 3639 (35) |
| NOACb | 2774 (4.6) | 112 (3.7) | 2662 (4.7) | 1072 (9.8) | 50 (8.6) | 1022 (9.8) |
| Warfarin | 8133 (14) | 363 (12) | 7770 (14) | 335 (3.0) | 24 (4.1) | 311 (3.0) |
| OACc | 10 677 (18) | 461 (15) | 10 216 (18) | 1407 (13) | 74 (13) | 1333 (13) |
| Laboratory data | ||||||
| 0 h hs-cTnT level (ng/L) | 10 (5–20) | 44 (21–108) | 9 (5–19) | 9 (5–20) | 50 (23–124) | 9 (4–18) |
| Historical hs-cTnT level (ng/L) | 10 (5–23) | 25 (12–69) | 10 (5–21) | 9 (4.–21) | 20 (10–64) | 9 (4–20) |
| Delta hs-cTnT changed (ng/L) | 2 (1–7) | 33 (9–145) | 2 (1–6) | 2 (1–8) | 42 (11–162) | 2 (0–7) |
| Time from historical hs-cTnT to 0 h hs-cTnT concentration (days) | 147 (40–384) | 152 (41–407) | 146 (40–383) | 465 (165–894) | 503 (147–942) | 463 (166–892) |
| . | Derivation cohort . | Validation cohort . | ||||
|---|---|---|---|---|---|---|
| . | All visits . | MI . | No MI . | All visits . | MI . | No MI . |
| Number of visits | 60 071 (100) | 2999 (5.0) | 57 072 (95) | 10 994 (100) | 582 (5.3) | 10 412 (95) |
| Age (years) | 68 (56–79) | 76 (67–86) | 68 (56–79) | 68 (54.0–79.0) | 75 (67–85) | 68 (53–78) |
| Women | 28 476 (47) | 1164 (2) | 27 312 (46) | 5436 (49) | 242 (42) | 5194 (50) |
| Comorbidities | ||||||
| Prior stroke | 6012 (10) | 470 (16) | 5542 (10) | 1514 (14) | 111 (19) | 1403 (14) |
| Prior MIa | 17 223 (29) | 1692 (56) | 15 531 (27) | 2449 (22) | 267 (46) | 2182 (21) |
| COPD | 7463 (12) | 403 (13) | 7060 (12) | 938 (8.5) | 49 (8.4) | 889 (8.5) |
| Heart failure | 8576 (14) | 583 (19) | 7993 (14) | 1563 (14) | 125 (22) | 1438 (14) |
| Diabetes | 10 263 (17) | 939 (31) | 9324 (16) | 2430 (22) | 210 (36) | 2220 (21) |
| Chronic kidney disease (eGFR < 60 mL/min/1.73 m2) | 4069 (6.8) | 464 (16) | 3605 (6.3) | 770 (7.0) | 84 (14) | 686 (6.6) |
| Current medications | ||||||
| Aspirin | 23 571 (39) | 1837 (61) | 21 734 (38) | 2889 (26) | 258 (44) | 2631 (25) |
| P2Y12 inhibitors | 8269 (14) | 746 (25) | 7523 (13) | 777 (7.1) | 84 (14) | 693 (6.7) |
| Beta-blockers | 33 037 (55) | 2079 (69) | 30 958 (54) | 2399 (22) | 171 (29) | 2228 (21) |
| ACE/ARB | 28 918 (48) | 1830 (61) | 27 088 (48) | 4012 (37) | 291 (50) | 3721 (36) |
| Statins | 24 664 (41) | 1662 (55) | 23 002 (40) | 3927 (36) | 288 (50) | 3639 (35) |
| NOACb | 2774 (4.6) | 112 (3.7) | 2662 (4.7) | 1072 (9.8) | 50 (8.6) | 1022 (9.8) |
| Warfarin | 8133 (14) | 363 (12) | 7770 (14) | 335 (3.0) | 24 (4.1) | 311 (3.0) |
| OACc | 10 677 (18) | 461 (15) | 10 216 (18) | 1407 (13) | 74 (13) | 1333 (13) |
| Laboratory data | ||||||
| 0 h hs-cTnT level (ng/L) | 10 (5–20) | 44 (21–108) | 9 (5–19) | 9 (5–20) | 50 (23–124) | 9 (4–18) |
| Historical hs-cTnT level (ng/L) | 10 (5–23) | 25 (12–69) | 10 (5–21) | 9 (4.–21) | 20 (10–64) | 9 (4–20) |
| Delta hs-cTnT changed (ng/L) | 2 (1–7) | 33 (9–145) | 2 (1–6) | 2 (1–8) | 42 (11–162) | 2 (0–7) |
| Time from historical hs-cTnT to 0 h hs-cTnT concentration (days) | 147 (40–384) | 152 (41–407) | 146 (40–383) | 465 (165–894) | 503 (147–942) | 463 (166–892) |
Data are presented as n (%), mean ± SD, or median with IQR.
Includes only MI as a primary diagnosis.
Includes treatment with Apixaban, Rivaroxaban, Dabigatran, or Epixaban.
Includes treatment with NOAC or warfarin.
The absolute change of hs-cTnT between the historical hs-cTnT and the 0 h cTnT concentration.
ACE/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; hs-cTnT, high-sensitivity cardiac troponin T; MI, myocardial infarction; NOAC, new oral anticoagulants; OAC, oral anticoagulants.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
